openPR Logo
Press release

Schizophrenia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Avanir, Boehringer Ingelheim, Cyclerion, Heptares, Medicell, Merck, Otsuka, Recognify, PsychoGenics, SyneuRx, Takeda, Valentech, Vigonvita

02-23-2024 02:13 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Schizophrenia Pipeline Assessment Covering Clinical Trials,

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Schizophrenia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Schizophrenia Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Schizophrenia Therapeutics Market.

The report provides a detailed description of the Schizophrenia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Schizophrenia Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Schizophrenia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Schizophrenia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Schizophrenia treatment market.

Learn More about the Clinical and Commercial Development Activities in the Schizophrenia Therapeutics Domain @
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Schizophrenia Therapeutics Analysis
Over 70+ pharma and biotech companies are currently dedicated to the development of therapies for Schizophrenia. Among the key players, Otsuka Pharmaceutical stands out for having Schizophrenia drug candidates in the most advanced stage of development, specifically in phase III clinical trials. Companies operating in the market collectively contribute to the advancement of treatment options for individuals affected by Schizophrenia, a complex and challenging mental health condition. Their efforts encompass a wide array of approaches and innovations aimed at improving the lives of patients and their families.

Schizophrenia Companies in the Therapeutics Market Include:
Some of the key companies in the Schizophrenia Market include ACADIA Pharmaceuticals, Addex Therapeutics, Avanir Pharmaceuticals, Boehringer Ingelheim, Cyclerion Therapeutics, Heptares Therapeutics, Karuna Therapeutics, Lyndra Therapeutics, Medicell S.A., Merck Sharp & Dohme, Minerva Neurosciences, Neurocrine Biosciences, Newron Pharmaceuticals, Otsuka Pharmaceutical, Pharmaceuticals Laboratories, Reviva Pharmaceuticals, Recognify Life Sciences, Sunivion / PsychoGenics / Otsuka Pharmaceuticals, SyneuRx International (Taiwan) Corp, Takeda, Valentech, Vigonvita Life Sciences and others.

Emerging and Marketed Schizophrenia Therapies Covered in the Report Include:
• Ulotaront: Otsuka Pharmaceutical
• AVP 786: Avanir Pharmaceuticals
• Luvadaxistat: Takeda
• CY6463: Cyclerion Therapeutics
• M4 PAMs: Addex Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Schizophrenia Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Schizophrenia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Schizophrenia Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Schizophrenia Current Treatment Patterns
4. Schizophrenia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Schizophrenia Late-Stage Products (Phase-III)
7. Schizophrenia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Schizophrenia Discontinued Products
13. Schizophrenia Product Profiles
14. Schizophrenia Companies
15. Schizophrenia Drugs
16. Dormant and Discontinued Products
17. Schizophrenia Unmet Needs
18. Schizophrenia Future Perspectives
19. Schizophrenia Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Schizophrenia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Avanir, Boehringer Ingelheim, Cyclerion, Heptares, Medicell, Merck, Otsuka, Recognify, PsychoGenics, SyneuRx, Takeda, Valentech, Vigonvita here

News-ID: 3397334 • Views:

More Releases from DelveInsight Business Research LLP

Postoperative Pain Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight
Postoperative Pain Market is Expected to Showcase a Significant Growth at a CAGR …
"The Postoperative Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Postoperative Pain pipeline products will significantly revolutionize the Postoperative Pain market dynamics" Key Takeaways from the Postoperative Pain Market Research Report • In 2022, the US captured the highest market share (85%), followed by Japan (7%), out of all the 7MM countries. • The Postoperative Pain market size in the
Amyotrophic Lateral Sclerosis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight
Amyotrophic Lateral Sclerosis Market is Expected to Showcase a Significant Growt …
"The Amyotrophic Lateral Sclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Amyotrophic Lateral Sclerosis pipeline products will significantly revolutionize the Amyotrophic Lateral Sclerosis market dynamics" Key Takeaways from the Amyotrophic Lateral Sclerosis Market Research Report • The total Amyotrophic Lateral Sclerosis diagnosed prevalent cases in the 7MM and China were 59,130 and 29,095 in 2021, growing at a
Schizophrenia Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight
Schizophrenia Market is Expected to Showcase a Significant Growth at a CAGR of X …
"The Schizophrenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics" Key Takeaways from the Schizophrenia Market Research Report • In the year 2021, the total Schizophrenia prevalent cases were 6.27 million in the 7MM which are expected to grow during the study period, i.e., 2019-2032. • The highest number of total
Metachromatic Leukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)
Metachromatic Leukodystrophy Pipeline, FDA Approvals, Clinical Trials Developmen …
DelveInsight's, "Metachromatic Leukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Metachromatic Leukodystrophy pipeline landscape. It covers the Metachromatic Leukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metachromatic Leukodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Metachromatic Leukodystrophy

All 5 Releases


More Releases for Schizophrenia

Schizophrenia Treatment Market Volume Analysis 2016-2026
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and
Schizophrenia Treatment Market size and forecast-2026
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and
Technological Advancements to Influence Schizophrenia Treatment Market Growth
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could
Global Schizophrenia Drug Market Research Report 2017
Qyresearchreports include new market research report "Schizophrenia Drug" to its huge collection of research reports. The report on the Schizophrenia Drug deals with the all its critical facts and figures that will help in creating an in-depth and insightful analysis. The market is elucidated in a holistic fashion that allows the users to gain a thorough analysis of the market, as developed using the factors that are likely to have a
Schizophrenia Drug Market Trends To 2022
Global Schizophrenia Drug Industry 2021 Market Research Report analyzed the current state in the definitions, classifications, applications and industry chain structure. The report also focuses on the development trends as well as history, competitive landscape analysis, and key regions etc in the international markets. Global Schizophrenia Drug Industry 2021 Market Research Report is a professionally prepared report comprising of in-depth information as well as knowledge which is helpful to the new